↓ Skip to main content

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
4 X users
patent
6 patents
wikipedia
4 Wikipedia pages

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer
Published in
Clinical Cancer Research, August 2017
DOI 10.1158/1078-0432.ccr-17-0533
Pubmed ID
Authors
Abstract

<p>Patients with metastatic colorectal cancer (CRC) suffer from disease relapse mainly due to cancer stem cells (CSC). Interestingly, they have an increased level of blood progastrin, a tumor-promoting peptide essential for the self-renewal of colon CSCs, which is also a direct b-catenin/Tcf4 target gene. In this study we aimed to develop a novel targeted therapy to neutralize secreted progastrin in order to inhibit Wnt signaling, CSCs and reduce relapses.</p> Experimental Design: <p>Antibodies (monoclonal and humanized) directed against progastrin were produced and selected for target specificity and affinity. After validation of their effectiveness on survival of CRC cell lines harboring B-RAF or K-RAS mutations, their efficacy was assessed in vitro and in vivo, alone or concomitantly with chemotherapy, on CSCs self-renewal capacity, tumor recurrence and Wnt signaling.</p> Results: <p>We show that anti-progastrin antibodies decrease self-renewal of CSCs both in vitro and in vivo, either alone or in combination with chemotherapy. Furthermore, migration and invasion of CRC cells are diminished; chemosensitivity is prolonged in SW620 and HT29 cells and post-treatment relapse is significantly delayed in T84 cells, xenografted nude mice. Finally, we show that the Wnt signaling activity in vitro is decreased, and, in transgenic mice developing Wnt-driven intestinal neoplasia, the tumor burden is alleviated, with an amplification of cell differentiation in the remaining tumors.</p> Conclusions:<br /><br />All together, these data show that humanized anti-progastrin antibodies might represent a potential new treatment for K-RAS mutated colorectal patients, for which there is a crucial unmet medical need.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Bachelor 6 15%
Researcher 4 10%
Student > Ph. D. Student 3 8%
Other 2 5%
Student > Doctoral Student 2 5%
Other 6 15%
Unknown 16 41%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 9 23%
Medicine and Dentistry 5 13%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Agricultural and Biological Sciences 3 8%
Chemical Engineering 1 3%
Other 3 8%
Unknown 15 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2024.
All research outputs
#2,705,819
of 34,350,842 outputs
Outputs from Clinical Cancer Research
#2,321
of 17,842 outputs
Outputs of similar age
#38,271
of 354,930 outputs
Outputs of similar age from Clinical Cancer Research
#48
of 235 outputs
Altmetric has tracked 34,350,842 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.3. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 354,930 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 235 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.